Emerging studies suggest this peptide, a dual activator targeting both GLP-1 and GIP , may represent a notable step forward for obesity treatment. Early human trials have indicated considerable reductions in body mass , possibly surpassing current body composition therapies . Nevertheless , more study is needed to completely understand its susta… Read More